AOD-9604 represents an elegant approach to fat metabolism research. By isolating the C-terminal lipolytic domain of human growth hormone (amino acids 177-191) and adding a stabilizing disulfide bridge, researchers created a peptide that retains HGH’s fat-burning properties while eliminating its effects on IGF-1, insulin sensitivity, and glucose tolerance. This selective profile enables metabolic research impossible with full HGH.

The clinical evidence is substantial. Phase 2b trials in Australia tested AOD-9604 in 300 obese individuals over 12 weeks. Results showed the peptide tripled weight loss compared to placebo, with weight loss rates remaining steady throughout — indicating no resistance development and suggesting longer protocols would yield greater results. Safety was indistinguishable from placebo across six human studies including both IV and oral administration.

Mechanistically, AOD-9604 operates through at least two pathways. The primary mechanism involves β3-adrenergic receptor activation on white adipose tissue, shifting fat cells from storage to utilization mode. However, research in β3-AR knockout mice revealed fat loss still occurs — confirming a secondary mechanism, potentially involving direct adipocyte apoptosis. This dual-pathway approach may explain the peptide’s robust efficacy.

Research applications have expanded beyond obesity. Intra-articular AOD-9604 injections show synergistic effects with hyaluronic acid in osteoarthritis models, improving pain scores and cartilage structure at both gross and microscopic levels — a finding relevant to the challenging problem of cartilage regeneration. Cardiovascular research suggests metabolic benefits beyond weight loss. For teams investigating fat metabolism, metabolic syndrome, osteoarthritis, or cardiovascular risk, AOD-9604 provides a uniquely targeted tool with extensive human safety data.

For research use only. Not for human consumption.